N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain

  title={N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain},
  author={{\'I}risz Szab{\'o} and Vikt{\'o}ria {\'E}. Varga and Szabolcs Dvor{\'a}csk{\'o} and Attila E. Farkas and T{\'i}mea K{\"o}rm{\"o}czi and R{\'o}bert Berkecz and Szilvia Kecsk{\'e}s and {\'A}kos Menyh{\'a}rt and Rita Frank and D{\'o}ra Hantosi and Nicholas V Cozzi and Ede Frecska and Csaba T{\"o}mb{\"o}ly and Istv{\'a}n A. Krizbai and Ferenc Bari and Eszter Farkas},

Figures from this paper

Impact of Two Neuronal Sigma-1 Receptor Modulators, PRE084 and DMT, on Neurogenesis and Neuroinflammation in an Aβ1–42-Injected, Wild-Type Mouse Model of AD
The effects of two S1R agonists, dimethyltryptamine (DMT) and PRE084, in an Aβ-induced in vivo mouse model characterizing neurogenic and anti-neuroinflammatory symptoms of AD, and the modulatory effects of S1r agonists were analyzed by immunohistochemical methods and western blotting are investigated.
Therapeutic Properties of Ayahuasca Components in Ischemia/Reperfusion Injury of the Eye
The potential therapeutic effect of MAO-A inhibitor harmaline in I/R-related eye diseases is revealed and DMT and harmaline exert opposite effects on important ocular proteins, each having a critical role in a different mechanism of eye-ischemia-related pathologies.
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
The review will address the current research findings for DMT from in vivo and in vitro studies as well as the possibility that these findings may be revealing the role of endogenous DMT in normal brain function.
Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders
Neuroinflammation in perioperative neurocognitive disorders: From bench to the bedside
High‐quality studies and recent advances from both clinical and preclinical studies are summarized and a broad view from the onset of PNDs to its potential therapeutic targets is provided to investigate the signaling pathways in P NDs for prevention and treatment.
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Evidence suggests that psychedelics and related compounds could prove useful for treating the behavioral and psychological symptoms of dementia (BPSD), and the robust effects of these compounds on structural and functional neuroplasticity and inflammation clearly warrant further investigation.
From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders.
Recent findings and information on how psychedelics may act therapeutically on cells within the central nervous system (CNS) during brain injuries and neurodegenerative diseases are discussed.
Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders
The three classic serotonergic naturally occurring psychedelics, psilocybin, ibogaine, and N, N-dimethyltryptamine are discussed, focusing on their pharmacological properties and clinical potential.
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
Assessment of potential ayahuasca and N,N-dimethyltryptamine (DMT) integration with contemporary healthcare seeks to provide a summary of selected literature regarding the mechanisms of action of DMT andAyahuasca; and assess to what extent the state of research can explain reports of unusual phenomenology.


N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats
The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells
Results reveal a novel and important role of DMT in human cellular physiology and postulate that this compound may be endogenously generated in situations of stress, ameliorating the adverse effects of hypoxic/ischemic insult to the brain.
Effects of the Sigma-1 Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-Phenylpropyl)-Piperazine Dihydro-Chloride on Inflammation after Stroke
The results suggest that sigma-1 receptor activation affects Iba1 expression in microglia/macrophages of the ischemic hemisphere after experimental stroke but does not affect post-stroke inflammatory mediators.
The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
The sigma-1 receptor is widely distributed in the central nervous system and periphery. Originally mischaracterized as an opioid receptor, the sigma-1 receptor binds a vast number of synthetic
A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity
N,N-dimethyltryptamine (DMT) is classified as a naturally occurring serotonergic hallucinogen of plant origin. It has also been found in animal tissues and regarded as an endogenous trace amine
Contribution of prostanoid signaling to the evolution of spreading depolarization and the associated cerebral blood flow response
It is suggested, that activation of EP4 receptors initiates vasodilation in response to SD in the intact brain, and – together with COX-1 derived prostanoids – shortens SD duration in the acute phase of ischemia.
Antidepressant fluvoxamine reduces cerebral infarct volume and ameliorates sensorimotor dysfunction in experimental stroke
It is suggested that the sigma-1 receptor agonist fluvoxamine reduces infarct volume and ameliorates neurological impairment even on postischemic treatment, and may be a promising new therapeutic approach for cerebral infarction.